CONCORDBIO Concord Biotech Q1 FY26 results (Apr–Jun 2025) and concall
Concord Biotech reported a soft Q1 FY26 characterized by 'revenue lumpiness' in the API segment and margin pressure from the newly commercialized Valthera injectable plant. Despite the 5% revenue dip and significant EBITDA contraction, management remains highly bullish on long-term prospects, maintaining their 25% CAGR target. The quarter was marked by strategic milestones, including US FDA approval for Teriflunomide tablets and the launch of the CDMO vertical in the US market.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 310 | 244 | 430 | 204 |
| EBITDA | 137 | 98 | 190 | 61 |
| Net profit | 99 | 74 | 142 | 43 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
